[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
According to previous reports, the Sputnik V vaccine, developed by the National Research Institute of Epidemiology and Microbiology Nikolai Gamaleja and conditionally registered on August 11, will be tested in the third phase by 40,000 volunteers. On the results of the first and second stage, according to a publication in the medical journal The Lancet last week, vaccinated individuals develop approximately one and a half times more antibodies than those who have been infected.
The head of the Ministry of Health also reported that delivery of the vaccine to clinics will begin next week, for the moment in small doses, because “all interests must be taken into account.”
Medical Director Anna Popova, head of Russia’s Consumer Protection Inspectorate (Roszpotrebnadzor), announced at an online meeting on infectious diseases on Monday that the Novosibirsk Vector Research Center will conduct clinical trials of its peptide antigen-based vaccine. before September 30. (In official Russian terminology, this means the completion of the first and second phases of testing.) It reports that 0.6 percent of Russians have been shown to be infected with the new coronavirus since the beginning of the year. In Russia, which according to Popova is the world leader in detection per 100,000 people, 172 types of domestic and foreign test systems are used. Moscow has helped 35 countries deliver nearly a million diagnostic tools.
More than 38.7 million laboratory tests have been performed in the country since the outbreak began, and about 270,000 during the last day. 210,523 people are under medical surveillance on suspicion of coronavirus infection.
Cover image: Getty Images
[ad_2]
